Schedule 13G ownership disclosure

CATABASIS PHARMACEUTICALS IN

Security class unavailable · CUSIP: 14875P206

Event date: 2021-03-31

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
1,950,000
Percent of class
10.1600%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001623632-21-000449
Form type
SC 13G/A
Filer
Cerevel Therapeutics Holdings, Inc.
CIK
CIK 1805387
Filed
Apr 09, 2021
Reporting period
Mar 31, 2021
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub